PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Combination of two pharmaceuticals proves effective in the treatment of multiple sclerosis

Combination of two pharmaceuticals proves effective in the treatment of multiple sclerosis
2012-11-26
(Press-News.org) Bonn/Magdeburg/Halle, 26/11/2012. A new substance class for the treatment of multiple sclerosis and other neurodegenerative diseases now promises increased efficacy paired with fewer side effects. To achieve this, a team of scientists under the leadership of Prof. Gunter Fischer (Max Planck Research Unit for Enzymology of Protein Folding, Halle/Saale, Germany) and Dr. Frank Striggow (German Center for Neurodegenerative Diseases (DZNE)) have combined two already approved pharmaceutical substances with each other using a chemical linker structure. The objectives of this combination are to ensure maximum brain cell protection on the one hand and the suppression of unwanted side effects on the other. The new class of substances has now been registered with the European Patent Office as the DZNE's first patent in the form of a joint patent application with the Max Planck Research Unit. "The patent approval process can take several years. During this phase we are planning to conclude the pre-clinical development. It is our aim to start with clinical research and development at the earliest possible time. Overall, we have identified substantial therapeutic potential as far as chronic and age-related neurodegenerative diseases are concerned," comments Dr. Frank Striggow.

Multiple sclerosis is an inflammatory disease that affects the central nervous system. It destroys the insulation of the nerve cell signaling system, the myelin sheaths of the neural axons. The consequence of this process is the malfunction of signaling and finally cell death resulting in permanent neurological problems. The cause of multiple sclerosis is that the body itself attacks the cellular components of the myelin sheaths, the oligodendrocytes. Hence, the team of scientists under the direction of Prof. Gunter Fischer and Dr. Frank Striggow embarked on a search for intervention options that could protect brain cells from these attacks. The goal was not only to prevent the damage and loss of brain cells, but also to develop a medication that has a positive impact on cell regeneration.

The used components of the Cyclosporine and FK506 (tacrolimus)-series have been utilized in a chemically slightly altered form as immunosuppressant medications for a long time. Both suppress the cellular immune defenses. This effect is necessary in conjunction with organ transplants, but otherwise problematic for the organism. The specific combination of the two substances amplifies the protective effect on the nerve cells thanks to different but synergistic efficacy mechanisms. The impact on the immune defense is reduced at the same time, which results in fewer side effects. Both of these achievements were corroborated by experiments. An application for a patent protecting this new class of active ingredients has now been filed. Ascenion GmbH and Max Planck Innovation both attend the project as utilization partners of the DZNE and of the Max Planck Society.



INFORMATION:

The German Center for Neurodegenerative Diseases (DZNE) conducts research to determine the causes of diseases that affect the nervous system and develops strategies for prevention, therapy and health care. It is a member of the Helmholtz Association with sites in Berlin, Bonn, Dresden, Göttingen, Magdeburg, Munich, Rostock/Greifswald, Tübingen and Witten. The DZNE cooperates closely with universities, university hospital and non-university institutions. In a number of research projects, DZNE scientists work in close partnership with the Max Planck Society. The joint patent application is a result of the cooperation of the DZNE and the Max Planck Research Unit for Enzymology of Protein Folding. The two are also partners in the BMBF Program "Spitzenforschung und Innovation in den Neuen Ländern" in conjunction with the ProNet-T3 Project, in which numerous other institutions are involved.


[Attachments] See images for this press release:
Combination of two pharmaceuticals proves effective in the treatment of multiple sclerosis

ELSE PRESS RELEASES FROM THIS DATE:

Putting more cores to work in server farms

2012-11-26
Streaming data, social networks, online games and services, databases – the number of interactions we have with the Internet is continually increasing. Every time we click on a link, we trigger an avalanche of computer operations that are then carried out in huge server farms. It's estimated that these massive installations are responsible for 2% of total world electricity consumption. EPFL Scientists are proposing a novel solution to help rein in this runaway consumption. By integrating the same kind of processor cores that are used in smartphones, the amount of energy ...

EARTH: Highlights of 2012

2012-11-26
Alexandria, VA – Considered individually, 2012's record high temperatures, droughts, wildfires, storms and diminished snowpack are not necessarily alarming. But combined, the fact that the first seven months of 2012 were hotter than the hottest on record, more than half of the U.S. counties were declared disaster areas due to drought, and the snowpacks were at all-time lows, these indicators are much more significant from a climate standpoint. Two questions then remain: Will we see the same thing in 2013? And how do we increase our ability to weather the storms and other ...

Lack of nutrients and metabolic syndrome linked to different subtypes of depression

2012-11-26
A low intake of folate and vitamin B12 increases the risk of melancholic depressive symptoms, according to a study among nearly 3,000 middle-aged and elderly Finnish subjects. On the other hand, non-melancholic depressive symptoms are associated with an increased risk for the metabolic syndrome. Based on these new observations, melancholic and non-melancholic depression may be separate depressive subtypes with different etiologies in terms of proinflammation and diet. The study was the first to look at these depressive sub-types separately. "The findings have practical ...

More Facebook friends means more stress, says report

2012-11-26
A large number of friends on Facebook may appear impressive but, according to a new report, the more social circles a person is linked to online the more likely social media will be a source of stress. A report from the University of Edinburgh Business School has found that the more groups of people in someone's Facebook friends, the greater potential to cause offence. In particular, adding employers or parents resulted in the greatest increase in anxiety. Stress arises when a user presents a version of themself on Facebook that is unacceptable to some of their online ...

Crash landings

2012-11-26
Diagnosing an injury in a swan is a far from easy undertaking. Not only are swans large, frequently weighing over 10 kg, but they are generally not happy at being handled and thus many of them can only be examined after sedation, which naturally represents a risk. The hip joints of many species of bird are known to be vulnerable to injury but swans are believed to suffer broken hips only rarely. The traditional way of examining the birds' hips relies on radiography but Gumpenberger and Scope now show that computerized tomography (CT) gives more reliable findings. The ...

Release all Tamiflu data as promised, argue researchers

2012-11-26
The latest correspondence is posted online today as part of the BMJ's open data campaign, aimed at persuading Roche to honour the promise it made almost three years ago to make key Tamiflu trial data available for independent scrutiny. Last week, Donald MacLean, Life Cycle Leader for Tamiflu, wrote to Professor Chris Del Mar in his capacity as coordinating editor of the Cochrane Acute Respiratory Infections Group, concerning "our debate on Tamiflu data." The Cochrane researchers say they object to Roche's suggestion that there is a debate on Tamiflu data. "There is ...

How does a volcanic crater grow? Grab some TNT and find out

2012-11-26
BUFFALO, N.Y. -- A new University at Buffalo study in the journal Geophysical Research Letters examines maar craters, which resemble the bowl-like cavities formed by meteorites but are in some ways more mysterious. Scientists often can discern pertinent details about meteorites -- when they struck, how large they were, the angle they approached Earth and other information -- by measuring the diameter and volume of the impact crater. Maar craters, which form when fissures of magma beneath Earth's surface meet groundwater, causing volcanic explosions, are not as telling, ...

BioMAP screening procedure could streamline search for new antibiotics

2012-11-26
Researchers at the University of California, Santa Cruz, have developed a new strategy for finding novel antibiotic compounds, using a diagnostic panel of bacterial strains for screening chemical extracts from natural sources. Public health officials warn of a looming antibiotic crisis due to the steady increase in antibiotic resistance and a dramatic decline in the development of new antibiotics. Most currently available antibiotics are derived from natural compounds produced by microorganisms such as bacteria and fungi. New antibiotics developed by drug companies are ...

New device hides, on cue, from infrared cameras

New device hides, on cue, from infrared cameras
2012-11-26
Cambridge, Mass. - November 26, 2012 - Now you see it, now you don't. A new device invented at the Harvard School of Engineering and Applied Sciences (SEAS) can absorb 99.75% of infrared light that shines on it. When activated, it appears black to infrared cameras. Composed of just a 180-nanometer-thick layer of vanadium dioxide (VO2) on top of a sheet of sapphire, the device reacts to temperature changes by reflecting dramatically more or less infrared light. Announced today in the journal Applied Physics Letters, and featured on its cover, this perfect absorber ...

Seizures linked to surgery drugs can be prevented by anesthetics, U of T team finds

2012-11-26
Two drugs commonly given during cardiac surgery can lead to convulsive seizures, but anesthetics can help cut the risk, according to new research from the Faculty of Medicine at the University of Toronto. Patients undergoing complex heart operations or trauma surgery are often given tranexamic acid (TXA) and aminocaproic acid (EACA) to reduce blood loss. But Faculty of Medicine researchers found these drugs are associated with a four-to-six-fold increase in post-operative seizures. The risk is highest for cardiac surgery patients – between three and seven and a half per ...

LAST 30 PRESS RELEASES:

Less intensive works best for agricultural soil

Arctic rivers project receives “national champion” designation from frontiers foundation

Computational biology paves the way for new ALS tests

Study offers new hope for babies born with opioid withdrawal syndrome

UT, Volkswagen Group of America celebrate research partnership

New Medicare program could dramatically improve affordability for cancer drugs – if patients enroll

Are ‘zombie’ skin cells harmful or helpful? The answer may be in their shapes

University of Cincinnati Cancer Center presents research at AACR 2025

Head and neck, breast, lung and survivorship studies headline Dana-Farber research at AACR Annual Meeting 2025

AACR: Researchers share promising results from MD Anderson clinical trials

New research explains why our waistlines expand in middle age

Advancements in muon detection: Taishan Antineutrino Observatory's innovative top veto tracker

Chips off the old block

Microvascular decompression combined with nerve combing for atypical trigeminal neuralgia

Cutting the complexity from digital carpentry

Lung immune cell type “quietly” controls inflammation in COVID-19

Fiscal impact of expanded Medicare coverage for GLP-1 receptor agonists to treat obesity

State and sociodemographic trends in US cigarette smoking with future projections

Young adults drive historic decline in smoking

NFCR congratulates Dr. Robert C. Bast, Jr. on receiving the AACR-Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research

Chimpanzee stem cells offer new insights into early embryonic development

This injected protein-like polymer helps tissues heal after a heart attack

FlexTech inaugural issue launches, pioneering interdisciplinary innovation in flexible technology

In Down syndrome mice, 40Hz light and sound improve cognition, neurogenesis, connectivity

Methyl eugenol: potential to inhibit oxidative stress, address related diseases, and its toxicological effects

A vascularized multilayer chip reveals shear stress-induced angiogenesis in diverse fluid conditions

AI helps unravel a cause of Alzheimer's disease and identify a therapeutic candidate

Coalition of Autism Scientists critiques US Department of Health and Human Services Autism Research Initiative

Structure dictates effectiveness, safety in nanomedicine

Mission accomplished for the “T2T” Hong Kong Bauhinia Genome Project

[Press-News.org] Combination of two pharmaceuticals proves effective in the treatment of multiple sclerosis